Source-grounded facts extracted from ADMA BIOLOGICS, INC.'s SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
ADMA BIOLOGICS, INC. shareholders approved Approval of, on a non-binding, advisory basis, the compensation of the Company's named executive officers at the 2026-06-02 meeting.
“Proposal No. 3 — Approval of the Say-on-Pay Proposal The vote with respect to the approval of, on a non-binding, advisory basis, the compensation of the Company's named executive officers was as follows: For Against Abstain Broker Non-Votes 168,169,866 Shares 7,730,690 Shares 326,116 Shares 23,040,875 Shares”
ADMA BIOLOGICS, INC. shareholders approved Ratification of the appointment of KPMG LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2026 at the 2026-06-02 meeting.
“Proposal No. 2 — Ratification of the Appointment of Independent Registered Public Accounting Firm The vote with respect to the ratification of the appointment of KPMG LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2026 was as follows: For Against Abstain 198,655,040 Shares 329,056 Shares 283,451 Shares”
ADMA BIOLOGICS, INC. shareholders approved Election of two nominees to serve as Class I directors until the Company's 2029 Annual Meeting of Stockholders and until such director's successor is duly elected and qualified, or such director's earlier resignation, removal or death at the 2026-06-02 meeting.
“Proposal No. 1 — Election of the Class I Directors The vote with respect to the election of each of the directors was as follows: Nominee For Withheld Broker Non-Votes Alison C. Finger 156,849,830 19,376,842 23,040,875 Eduardo Rene Salas 171,947,523 Shares 4,279,149 Shares 23,040,875 Shares”
ADMA BIOLOGICS, INC. reported FY 2026 results: revenue $530 million to $560 million, net income $170 million to $200 million. Guidance initiated.
“FY 2026 total revenue expected to be $530 million to $560 million • FY 2026 Adjusted Net Income expected to be $170 million to $200 million • FY 2026 Adjusted EBITDA expected to be $265 million to $300 million”
ADMA BIOLOGICS, INC. reported three months ended March 31, 2026 results: revenue $114.5 Million, net income Adjusted Net Income (1) of $40.7 Million.
“--- EX-99.1 2 ef20072554_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 ADMA Biologics Reports First Quarter 2026 Financial Results and Provides Business Update 1Q 2026 Total Revenue of $114.5 Million, Flat Year-Over-Year 1Q 2026 ASCENIV Revenue +28% Year-Over-Year; BIVIGAM Revenue -54% Year-Over-Year 1Q 2026 Adjusted Net Income (1) of $40.7 Million, 22% Year-Over-Year Growth”
ADMA BIOLOGICS, INC. incurred revolving credit of $225 million with JPMorgan Chase Bank, N.A. at 150 basis points to 200 basis points over the alternate base rate and 250 basis maturing August 5, 2028.
“The Credit Agreement provides for $300 million of senior secured credit facilities, consisting of (a) a term loan in the aggregate principal amount of $75 million (the "Term Loan Facility") and (b) a revolving credit facility in the aggregate principal amount of $225 million (the "Revolving Facility").”
ADMA BIOLOGICS, INC. incurred term loan of $75 million with JPMorgan Chase Bank, N.A. at 150 basis points to 200 basis points over the alternate base rate and 250 basis maturing August 5, 2028.
“The Credit Agreement provides for $300 million of senior secured credit facilities, consisting of (a) a term loan in the aggregate principal amount of $75 million (the "Term Loan Facility") and (b) a revolving credit facility in the aggregate principal amount of $225 million (the "Revolving Facility").”
ADMA BIOLOGICS, INC. incurred credit facility of $300 million with JPMorgan Chase Bank, N.A. at 150 basis points to 200 basis points over the alternate base rate and 250 basis maturing August 5, 2028.
“into a Credit Agreement (the “Credit Agreement”), with the lenders party thereto and JPMorgan Chase Bank, N.A., as administrative agent. The Credit Agreement provides for $300 million of senior secured credit facilities, consisting of (a) a term loan in the aggregate principal amount of $75 million (the “Term Loan Facility”) and (b) a revolving credit”
Eduardo Rene Salas was appointed as Class I Director at ADMA BIOLOGICS, INC..
“On December 30, 2024, the Board of Directors (the “Board”) of ADMA Biologics, Inc. (the “Company”) appointed Eduardo Rene Salas to serve on the Board as a Class I director with a term expiring at the Company’s 2026 annual meeting of stockholders.”
Bryant E. Fong resigned as member of the Board of Directors at ADMA BIOLOGICS, INC..
“On November 19, 2024, Bryant E. Fong notified ADMA Biologics, Inc. (the “Company”) that he resigned, effective immediately, as a member of the Company’s Board of Directors (the “Board”) and any committees of the Board in order to devote more time to his roles as Managing Director of Biomark Capital Fund and as Partner and Co-Portfolio Manager of Stonepine Capital Management.”
ADMA BIOLOGICS, INC. engaged KPMG LLP as its auditor.
“On October 31, 2024, ADMA Biologics, Inc. (the “Company”) and KPMG LLP (“KPMG”) executed an agreement pursuant to which KPMG will initiate its engagement and serve as the Company’s new independent registered public accounting firm effective upon the filing of the Company’s Quarterly Report on Form 10-Q for the fiscal quarter ended September 30, 2024.”
Brad Tade changed role as Chief Financial Officer and Treasurer at ADMA BIOLOGICS, INC..
“Brad Tade, former Vice President, Financial Operations of ADMA Biologics, Inc. (the "Company"), was promoted to Chief Financial Officer and Treasurer of the Company”
ADMA BIOLOGICS, INC. reported three months ended March 31, 2024 results: revenue $81.9 Million, net income $17.8 Million. Guidance raised.
“ADMA Biologics Announces First Quarter 2024 Financial Results and Provides Business Update 1Q 2024 Total Revenue of $81.9 Million, a 44% Increase Y-o-Y 1Q 2024 GAAP Net Income of $17.8 Million, a $24.6 Million Increase Y-o-Y”
Kaitlin Kestenberg changed role as Chief Operating Officer and Senior Vice President, Compliance at ADMA BIOLOGICS, INC..
“Effective April 1, 2024 (the “Effective Date”), Kaitlin Kestenberg, former Senior Vice President, Compliance & Project Operations of ADMA Biologics, Inc. (the “Company”), was promoted to Chief Operating Officer and Senior Vice President, Compliance of the Company”
ADMA BIOLOGICS, INC. reported the full year 2023 and the three months ended December 31, 2023 results: revenue Total revenues were $73.9 million for the quarter ended December 31, 2023. Guidance raised.
“ADMA Biologics, Inc. issued a press release announcing its financial results for the full year 2023 and the three months ended December 31, 2023”
Brian Lenz changed role as Chief Financial Officer at ADMA BIOLOGICS, INC..
“Effective as of April 1, 2024, Brian Lenz, Executive Vice President, Chief Financial Officer & General Manager, ADMA BioCenters, will transition from these positions to a consulting role with the Company (the “CFO Transition”).”
ADMA BIOLOGICS, INC. reported fourth quarter and full year 2023 results: revenue $72-74 Million. Guidance raised.
“ADMA Biologics Announces Preliminary Fourth Quarter 2023 Revenue and Provides Business Update 4Q 2023 Preliminary Unaudited Total Revenue of $72-74 Million FY 2023 Preliminary Unaudited Total Revenue of $256-258 Million FY 2024 and 2025 Total Revenue Guidance Increased to More than $320 Million and $370 Million”
ADMA BIOLOGICS, INC. incurred credit facility of $130 million in total senior secured credit facilities with Ares Capital Corporation and certain credit funds affiliated with Ares Capital Corporation (collectively, “Ares”) at adjusted Term SOFR for a three‐month tenor plus 6.50% for the Initial Term Loan maturing December 20, 2027.
“On December 18, 2023, (the “Ares Closing Date”), ADMA Biologics, Inc. (the “Company”) and all of the Company’s subsidiaries entered into a Credit Agreement (the “Ares Credit Agreement”) with Ares Capital Corporation and certain credit funds affiliated with Ares Capital Corporation (collectively, “Ares”). The Ares Credit Agreement provides for $130 million in total senior secured credit facilities (the “Ares Credit Facilities”), consisting of (a) an initial term loan in the aggregate principal amount of $62,500,000 (the “Initial Term Loan Facility”) and (b) a revolving credit facility in the aggregate principal amount of up to $72,500,000 (the “Revolving Facility”).”
ADMA BIOLOGICS, INC. terminated Hayfin Credit Facility with Hayfin Services LLP (effective 2023-12-18).
“On the Ares Closing Date, the Company used the proceeds of the Ares Credit Facilities, along with cash on hand, to terminate and pay in full all of the outstanding obligations under the Company’s previous senior credit facility with Hayfin Services LLP (the “Hayfin Credit Facility")”
ADMA BIOLOGICS, INC. entered into Ares Credit Agreement with Ares Capital Corporation and certain credit funds affiliated with Ares Capital Corporation valued at $130 million (effective 2023-12-18).
“On December 18, 2023, (the “Ares Closing Date”), ADMA Biologics, Inc. (the “Company”) and all of the Company’s subsidiaries entered into a Credit Agreement (the “Ares Credit Agreement”) with Ares Capital Corporation and certain credit funds affiliated with Ares Capital Corporation (collectively, “Ares”).”
ADMA BIOLOGICS, INC. reported three months ended September 30, 2023 results: revenue $67.3 Million, net income $2.6 Million. Guidance raised.
“ADMA Biologics Announces Third Quarter 2023 Financial Results and Provides Business Update 3Q2023 Total Revenues of $67.3 Million, a 64% Y-o-Y Increase First-Time Positive GAAP Net Income of $2.6 Million”
Alison C. Finger was appointed as Class I director at ADMA BIOLOGICS, INC..
“On September 28, 2023, the Board of Directors (the “Board”) of ADMA Biologics, Inc. (the “Company”) appointed Alison C. Finger to serve on the Board as a Class I director with a term expiring at the Company’s 2026 annual meeting of stockholders.”
ADMA BIOLOGICS, INC. reported FY2025 results: revenue $325 Million. Guidance raised.
“FY2024 and 2025 Total Revenue Guidance Increased to $275 Million and $325 Million or More, Respectively”
ADMA BIOLOGICS, INC. reported FY2024 results: revenue $275 Million. Guidance raised.
“FY2024 and 2025 Total Revenue Guidance Increased to $275 Million and $325 Million or More, Respectively”
ADMA BIOLOGICS, INC. reported FY2023 results: revenue $240 Million. Guidance raised.
“FY2023 Total Revenue Now Expected to Exceed $240 Million, Increased from $220 Million”
ADMA BIOLOGICS, INC. reported the three months ended June 30, 2023 results: revenue $60.1 Million. Guidance raised.
“2 brhc20057230_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 ADMA Biologics Announces Second Quarter 2023 Financial Results and Provides Business Update 2Q2023 Total Revenues of $60.1 Million, a 77% Y-o-Y Increase 2Q2023 Adjusted EBITDA(1) of $6.4 Million, a 160% Q-o-Q Improvement 2Q2023 Adjusted Net Loss(2) of $3.6 Million, a 74% Y-o-Y Improvement FY2023 Total”
ADMA BIOLOGICS, INC. shareholders approved Ratification of the appointment of CohnReznick LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2023 at the 2023-06-06 meeting.
“The vote with respect to the ratification of the appointment of CohnReznick LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2023 was as follows: For Against Abstain 178,835,482 407,959 230,823”
ADMA BIOLOGICS, INC. shareholders approved Election of Bryant E. Fong to serve as a Class I director until the Company’s 2026 Annual Meeting of Stockholders and until his successor is duly elected and qualified, or until his earlier resignation, removal or death at the 2023-06-06 meeting.
“The vote with respect to the election of the director was as follows: Nominee For Withheld Broker Non-Votes Bryant E. Fong 104,032,764 43,796,163 31,645,337”
ADMA BIOLOGICS, INC. reported FY2023 results: revenue $220 Million. Guidance raised.
“FY2023 Total Revenue Now Expected to Exceed $220 Million, Increased from $210 Million”
ADMA BIOLOGICS, INC. reported first quarter 2023 results: revenue $57 Million, net income Net Loss of $6.8 Million.
“1Q2023 Total Revenues of $57 Million, a 96% Y-o-Y Increase 1Q2023 Net Loss of $6.8 Million, a 73% Y-o-Y Improvement”
ADMA BIOLOGICS, INC. amended Amendment No. 2 with Hayfin Services LLP and the lenders identified therein (effective 2023-05-01).
“On May 1, 2023 (the “Amendment Closing Date”), ADMA Biologics, Inc. (the “Company”) entered into Amendment No. 2 (the “Amendment”) to the Credit Agreement and Guaranty, dated as of March 23, 2022, as previously amended by that certain Amendment No. 1 to the Credit Agreement and Guaranty, dated as of March 22, 2023 (the “Hayfin Credit Agreement”), with Hayfin Services LLP and the lenders identified therein (collectively, “Hayfin”).”
ADMA BIOLOGICS, INC. reported the three months ended December 31, 2022 results: revenue $50.0 million.
“Total revenues for the quarter ended December 31, 2022 were $50.0 million, as compared to $26.4 million during the fourth quarter of 2021, an increase of $23.6 million, or approximately 90%.”
ADMA BIOLOGICS, INC. updated its 2023 guidance (initiated).
“ADMA currently anticipates full year 2023 total revenues of $210 million or more.”
ADMA BIOLOGICS, INC. reported fourth quarter and full year 2022 results: revenue preliminary, unaudited revenue for the fourth quarter ended December 31, 2022 to be approximately $49-50 million. Guidance reaffirmed.
“ADMA Biologics, Inc. (the “Company”) issued a press release announcing its preliminary unaudited fourth quarter and full year 2022 revenues and providing 2023 financial guidance.”
ADMA BIOLOGICS, INC. entered into Underwriting Agreement with Raymond James & Associates, Inc., acting as representative of the several underwriters named therein valued at approximately $60 million (effective 2022-12-07).
“On December 7, 2022, ADMA Biologics, Inc., a Delaware corporation (the “Company”) priced its previously announced underwritten public offering pursuant to which the Company has agreed to issue and sell an aggregate of 20,979,020 shares (the “Shares”) of its common stock, par value $0.0001 per share (the “Common Stock”), at a price to the public of $2.86 per share, for aggregate gross proceeds of approximately $60 million, before deducting underwriting discounts and commissions and estimated fees and expenses payable by the Company in connection with the offering (the “Offering”). Pursuant to the terms of the Underwriting Agreement (the “Underwriting Agreement”) entered into by and between the Company and Raymond James & Associates, Inc., acting as representative of the several underwriters named therein (the “Underwriters”)”
ADMA BIOLOGICS, INC. reported year-ended December 31, 2022 results: revenue between $152 million and $154 million.
“ADMA preliminarily estimates that its total revenue for the quarter- and year-ended December 31, 2022 will be between $48 million and $50 million and $152 million and $154 million, respectively.”
ADMA BIOLOGICS, INC. reported quarter-ended December 31, 2022 results: revenue between $48 million and $50 million.
“ADMA preliminarily estimates that its total revenue for the quarter- and year-ended December 31, 2022 will be between $48 million and $50 million and $152 million and $154 million, respectively.”
ADMA BIOLOGICS, INC. reported the three months ended September 30, 2022 results: revenue $41.1 million. Guidance raised.
“2 brhc10043955_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 ADMA Biologics Announces Third Quarter 2022 Financial Results and Provides Business Update 3Q2022 Total Revenues Were $41.1 Million, a 99% Y-o-Y Increase Grew 3Q2022 Gross Profit to $9.7 Million, a $9.3 Million Y-o-Y Increase Raising FY 2022 Total Revenue Guidance to $145 Million From $130 Million Previously”
Young T. Kwon was appointed as Class II director at ADMA BIOLOGICS, INC..
“On October 15, 2021, the Board of Directors (the “Board”) of ADMA Biologics, Inc. (the “Company”) appointed Young T. Kwon, Ph.D. to serve on the Board as a Class II director with a term expiring at the Company’s 2024 annual meeting of stockholders.”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.